Use of Sirolimus to Facilitate Steroid Withdrawal From a Cyclosporine Regimen

Transplantation Proceedings

Volumn 38, Issue 9, 2006, Pages 2842-2846

  Kahan, B D ^a   Podbielski, J ^a   Schoenberg, L ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PREDNISONE; RAPAMYCIN; STEROID;

ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOG RANK TEST; LONG TERM CARE; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL ANALYSIS; STEROID THERAPY; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; CYCLOSPORINE; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REOPERATION; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750931013     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.09.001     Document Type: Article

References (10)

1. Hricik D.E. Steroid withdrawal in renal transplantation. Transplant Proc 33 (2001) 3261
2. Kahan B.D., Podbielski J., Napoli K.L., et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66 (1998) 1040
3. Mahalati K., and Kahan B.D. Sirolimus permits steroid withdrawal from a cyclosporine regimen. Transplant Proc 33 (2001) 1270
4. Lisik W., and Kahan B.D. Proliferation signal inhibitors: chemical, biological and clinical properties. Transplant Rev 19 (2006) 186
5. Kahan B.D., Napoli K.L., Kelly P.A., et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 14 (2000) 97
6. Amante A.J., and Kahan B.D. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem 42 (1996) 1294
7. Citterio F., Sparacino V., Altieri P., et al. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid. Transplant Proc 37 (2005) 827
8. Kahan B.D. The role of rapamycin in chronic rejection prophylaxis: a theoretical consideration. Graft 1 2 Suppl II (1998) 93
9. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694
10. Eisen H.J., Tuzcu E.M., Dorent R., et al. RAD B253 Study Group: everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847